Financial Performance - For the six months ended December 31, 2024, the company reported revenue of HKD 161,056,000, a decrease of 15.4% compared to HKD 190,330,000 for the same period in 2023[2]. - The gross profit for the same period was HKD 21,130,000, representing a gross margin of 13.1%, compared to HKD 16,795,000 in 2023[2]. - The company incurred a loss before tax of HKD 11,202,000, compared to a loss of HKD 2,845,000 in the previous year, indicating a significant increase in losses[3]. - The net loss for the period was HKD 13,054,000, compared to HKD 4,030,000 in 2023, reflecting a year-over-year increase of 224.5%[3]. - Basic and diluted loss per share was HKD 7.97, compared to HKD 3.93 for the same period last year[3]. - The company reported a total comprehensive loss of HKD 13,564,000 for the period, compared to a comprehensive income of HKD 1,500,000 in the previous year[5]. - The group reported a loss attributable to the owners of the company of approximately HKD 13,661,000 for the six months ending December 31, 2024, compared to a loss of HKD 4,030,000 for the same period in 2023[12][22]. - The loss attributable to the company's owners increased to approximately HKD 13,661,000 for the six months ending December 31, 2024, compared to approximately HKD 6,734,000 for the six months ended December 31, 2023[39]. Assets and Liabilities - Non-current assets decreased to HKD 87,468,000 from HKD 95,100,000 as of June 30, 2024[7]. - Current assets also declined to HKD 92,870,000 from HKD 114,398,000, indicating a reduction in liquidity[7]. - Total liabilities amounted to HKD 237,410,000, down from HKD 253,847,000, showing a decrease in overall debt[8]. - The company's equity attributable to owners was a loss of HKD 93,174,000, compared to a loss of HKD 79,253,000 as of June 30, 2024[8]. - The net current liabilities of the group as of December 31, 2024, were approximately HKD 144,540,000, indicating significant uncertainty regarding the group's ability to continue as a going concern[12]. - Total debt as of December 31, 2024, was approximately HKD 146,879,000, up from approximately HKD 135,902,000 as of June 30, 2024[40]. - The net debt to total assets ratio increased to approximately 80.5% as of December 31, 2024, compared to approximately 63.8% as of June 30, 2024[40]. Revenue Sources - For the six months ending December 31, 2024, the revenue from the manufacturing and sales of modified starch and other biochemical products was approximately HKD 161,056,000, a decrease of 15.4% compared to HKD 190,330,000 for the same period in 2023[17][18]. - The group’s segment profit from modified starch and other biochemical products was HKD 4,522,000 for the six months ending December 31, 2024, down from HKD 7,959,000 for the same period in 2023[22]. - Segment profit from the manufacturing and sales of modified starch and biochemical products was approximately HKD 4,522,000 for the review period, down from approximately HKD 7,959,000 for the six months ended December 31, 2023[42]. Strategic Plans - The group plans to pursue strategic acquisitions to gain new opportunities in the Chinese market and strengthen its revenue and profit base[14]. - The group is actively seeking projects with growth potential for acquisition or investment and is in discussions with various parties regarding such opportunities[14]. - The company is actively seeking acquisition opportunities to gain new market opportunities in China and strengthen its revenue and profit base[42]. - The company is implementing measures to improve its financial situation, including discussions with potential investors to raise sufficient funds[42]. Expenses and Financial Management - Administrative expenses increased by 28.8% from approximately HKD 9,412,000 for the six months ended December 31, 2023, to approximately HKD 12,126,000 for the six months ending December 31, 2024[39]. - Sales expenses decreased by 27.7% from approximately HKD 6,938,000 for the six months ended December 31, 2023, to approximately HKD 5,432,000 for the six months ending December 31, 2024[39]. - The income tax expense for the six months ending December 31, 2024, was HKD 1,852,000, compared to HKD 1,185,000 for the same period in 2023[23]. Shareholder Information - The company did not recommend any interim dividend for the six months ended December 31, 2024, consistent with the previous period[27]. - The board has decided not to recommend an interim dividend for the six months ended December 31, 2024[44]. - The interim financial results for the six months ending December 31, 2024, will be published and sent to shareholders shortly[52]. Compliance and Governance - The audit committee currently consists of only two independent non-executive directors, which does not meet the minimum requirement of three members as per listing rules[51]. - The company is actively seeking suitable candidates to fill the vacancies in the audit committee to comply with listing rules by May 14, 2025[51]. Securities and Financing - The company has secured loans of approximately HKD 4,438,000 and has access to additional financing of approximately HKD 65,562,000 from its ultimate holding company to support its operations[12][16]. - The company has agreed to amend the terms of existing convertible bonds, including but not limited to the conversion price and maturity date[35]. - The company has not recognized any deferred tax liabilities due to the absence of taxable profits in Hong Kong for the periods under review[24]. - The company has not purchased, sold, or redeemed any of its listed securities during the six months ended December 31, 2024[45].
玮俊生物科技(00660) - 2025 - 中期业绩